Wall Street brokerages predict that TG Therapeutics Inc (NASDAQ:TGTX) will announce earnings per share (EPS) of ($0.37) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.43) to ($0.30). The firm is scheduled to report its next quarterly earnings results on Tuesday, February 11th.
According to Zacks, analysts expect that TG Therapeutics will report full year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.19) to ($1.83). For the next financial year, analysts forecast that the business will report earnings of ($1.45) per share, with EPS estimates ranging from ($1.98) to ($0.76). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.33). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 123,130.93% and a negative return on equity of 2,411.79%.
Shares of NASDAQ TGTX traded down $0.13 during mid-day trading on Friday, hitting $7.80. The company had a trading volume of 1,428,800 shares, compared to its average volume of 1,612,497. TG Therapeutics has a 12 month low of $3.32 and a 12 month high of $9.38. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 2.77. The firm’s 50 day simple moving average is $6.40 and its two-hundred day simple moving average is $6.92.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in TG Therapeutics by 5.0% in the 2nd quarter. SG Americas Securities LLC now owns 30,858 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 1,481 shares in the last quarter. Rhumbline Advisers boosted its position in TG Therapeutics by 2.1% during the 3rd quarter. Rhumbline Advisers now owns 95,679 shares of the biopharmaceutical company’s stock worth $537,000 after acquiring an additional 1,976 shares during the period. Aperio Group LLC bought a new position in shares of TG Therapeutics in the second quarter worth $32,000. Parametric Portfolio Associates LLC grew its stake in shares of TG Therapeutics by 45.4% in the second quarter. Parametric Portfolio Associates LLC now owns 21,152 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 6,609 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in shares of TG Therapeutics by 1,119.0% in the second quarter. Bank of Montreal Can now owns 8,143 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 7,475 shares in the last quarter. 52.97% of the stock is currently owned by institutional investors.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Featured Article: Understanding the different types of bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.